Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, pilot study designed to evaluate the safety and feasibility of
combining anastrozole and palbociclib in the following two cohorts: Cohort A) as first-line
therapy and Cohort B) as maintenance therapy after first-line chemotherapy in postmenopausal
patients with HR-positive, HER2-negative metastatic breast cancer. Pre- and perimenopausal
women must receive therapy with an LHRH agonist. The LHRH agonist will be by choice for an
approved LHRH agonist administered according to its respective prescribing information.
Following informed consent and eligibility check, subjects will be enrolled to either Cohort
A or Cohort B.